NTT Com Launches Renewed SkyWay SDK for More Versatile Development of Online Communication Services
31.1.2023 13:01:00 EET | Business Wire | Press release
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT group, announced today the immediate launch of the renewed SkyWay software development kit (SDK). The new SkyWay SDK makes it easier than ever to implement real-time voice, video and data communication for applications and websites.
People interested planning or developing online communication services may apply to attend a free webinar in person (50 people) or online (100 people) to learn about the renewed SkyWay SDK at NTT Communications' Tokyo headquarters from 3:00pm (JST) on February 23.
Simple to use and supported with extensive documentation, SkyWay does not require special technical skills or knowledge of voice/video communication or constructing servers, and can be used for a wide range of applications, such as online lessons, IoT and robots. To date, SkyWay has been deployed for the development of more than 20,000 services.
SkyWay is suitable for diverse call formats including voice and video, one-to-one and group calls, and video communication while sharing screens. It also is a multiplatform SDK for developing communication services suited to specific industries and business categories. SkyWay assures high-quality real-time communication, as evidenced by its service uptime rate of 99.96% in fiscal 2021. It also achieves high-quality overseas calls by setting up servers to relay communications to/from Asia, North America and Europe.1 What's more, SkyWay may be used at no charge for service verification and development until the users service is actually launched. Furthermore, fees are adjusted to the scale of service and billing is implemented on a pay-as-you-go billing basis.
Due to the COVID-19 pandemic, online communication has rapidly diversified and now commonly includes events involving dozens of people as well as communication robots. In response, NTT Com decided to upgrade SkyWay's architecture and release it as a new service with enhanced functions for increased versatility, including:
- More simultaneous callers (expanded from 20 to 100 max.)
- Terminal load reduction according to end-user environment (simulcasting2 and API for flexible media transmission/reception, such as only specific video/audio)
- Authentication and authorization for controlling transmission of video/audio to each end user
The following are two examples of SkyWay's expanded functionality.
1. Virtual office
SkyWay can be used to create a system for an office-wide presentation reaching up to 100 people, with simulcasting allowing people to receive audio/video suitably adjusted to each user, such as low-resolution video to reduce system and battery load for mobile devices or terminals with low processing power. Also, participation can be controlled for private conferences.
2. Remote work support
SkyWay also can be used to create a system that allows a supervisor to remotely instruct multiple people at a worksite, using video for detailed directions and only audio if simple verbal directions are sufficient. Selective use of video and/or audio enables the system to reach many people with minimum load.
Service applications will be accepted from January 31. For details, please visit the website or contact a NTT Com sales representative, and for service rates, please see here. (Partially in Japanese only)
Looking ahead, NTT Com expects to further upgrade SkyWay by expanding the scale of voice and video calls, enhancing data communications for synchronization of more people, and supporting gaming platforms for live streaming and the metaverse. In addition, voice and video call experiences will be improved. Also, new SkyWay functions for measuring quality and analyzing problems will increasingly upgrade video and voice in diverse environments. Going forward, NTT Com will continue to develop SkyWay-related business to support the further evolution of real-time communication and its easy implementation by nonexperts in a world where people communicate meaningfully through the power of digital technology.
For more information about SkyWay, please visit here.
1 Technology that enables a terminal to select the most appropriate relay device in order to minimize delay between terminals (granted patent No. 6254620).
2 Technology for transmitting the same video to different terminals using different bitrates, such as low-resolution to mobile devices with limited processing power and bandwidth and high-resolution to PCs.
About NTT Communications
NTT Communications solves global technology challenges by helping enterprises utilize managed IT-infrastructure solutions to overcome complexity and risk in their IT environments. These solutions are backed by our worldwide infrastructure, including industry-leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2 of the world's most advanced data-center facilities. As the core provider of the DOCOMO group's enterprise-business services and solutions, we create value by providing global-scale support for restructuring in industry and society, new workstyles and digital transformation in communities. Together with NTT Ltd., NTT Data and NTT DOCOMO, we are the NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005787/en/
Contact information
For more information
SkyWay Promotion Office
Platform Service Division
NTT Communications Corporation
E-mail: skyway@ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom